SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-310169
Filing Date
2022-12-21
Accepted
2022-12-21 17:25:33
Documents
17
Period of Report
2022-12-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d399008d8k.htm   iXBRL 8-K 31241
2 EX-5.1 d399008dex51.htm EX-5.1 10105
3 EX-99.1 d399008dex991.htm EX-99.1 14020
4 EX-99.2 d399008dex992.htm EX-99.2 113570
8 GRAPHIC g399008g1221133513609.jpg GRAPHIC 3252
9 GRAPHIC g399008g1221134219834.jpg GRAPHIC 1414
  Complete submission text file 0001193125-22-310169.txt   346666

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA oric-20221221.xsd EX-101.SCH 2860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE oric-20221221_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oric-20221221_pre.xml EX-101.PRE 11714
11 EXTRACTED XBRL INSTANCE DOCUMENT d399008d8k_htm.xml XML 3480
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 221479190
SIC: 2834 Pharmaceutical Preparations